Synthetic Biologics Inc (NYSE American:SYN)

0.2591
Delayed Data
As of May 23
 -0.0059 / -2.23%
Today’s Change
0.19
Today|||52-Week Range
1.05
-49.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$35.0M

Company Description

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Contact Information

Synthetic Biologics, Inc.
9605 Medical Center Drive
Rockville Maryland 20850
P:(301) 417-4364
Investor Relations:

Employees

Shareholders

Other institutional9.27%
Mutual fund holders4.17%
Individual stakeholders13.66%

Top Executives

Steven A. ShallcrossCEO, CFO, Secretary & Treasurer
Michael KalekoSenior Vice President-Research & Development
Joseph SlimanChief Medical Officer
Deb MathewsVice President-Medical Affairs
Raymond D. StapletonSenior Vice President-Manufacturing